1123 Forma
BioCentury & Getty Images

Product Development

How Forma is working to show the sickle cell community it’s in for the long haul

Forma is prioritizing sickle cell patient engagement with a focus on policy advocacy and COVID-19 safety

With early data coming in for its sickle cell program, Forma is prioritizing patient engagement, with a focus on policy advocacy and COVID-19 safety.

Nov 21, 2020 | 4:02 AM GMT

As early clinical evidence for its sickle cell disease candidate grows, Forma is prioritizing building relationships with the patient community, with a focus on long-term policy goals and COVID-19 safety protections.

Forma Therapeutics Inc. (NASDAQ:FMTX) CEO Frank Lee said it’s crucial for companies to prove that their commitment to patient engagement goes beyond clinical trial recruitment and drug sales. “We’re a relative newcomer to the space. Building relationships takes many years of being there for the community,” said Lee.

A key step was appointing

Read the full 1498 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers